Lung Cancer
Volume 62, Issue 1 , Pages 72-77 , October 2008

Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer

  • Se Hoon Park

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul 135-710, Republic of Korea
    • ,
  • Junshik Hong

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Young Saing Kim

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Yujin Kim

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Sun Young Kyung

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Chang Hyeok An

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Sang Pyo Lee

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Jeong Woong Park

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Sung Hwan Jeong

      Affiliations

    • Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Jinny Park

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Eun Kyung Cho

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 32 460 3817; fax: +82 32 460 3233.
    • ,
  • Dong Bok Shin

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea
    • ,
  • Jae Hoon Lee

      Affiliations

    • Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Republic of Korea

Received 22 October 2007 ,Revised 1 February 2008 ,Accepted 1 February 2008.

References 

  1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat. 2002;34:77–83
  2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311: 899–909.
  3. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087–1100
  4. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–353
  5. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285–4291
  6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  7. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–3024
  8. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004;22:254–261
  9. Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006;17:1111–1119
  10. Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990;8:886–891
  11. Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 1997;8:525–529
  12. Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 1999;17:914–920
  13. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478–1484
  14. Popa IE, Stewart K, Smith FP, Rizvi NA. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer. 2002;95:1714–1719
  15. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164–2168
  16. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16:90–96
  17. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study. Br J Cancer. 2004;91:1996–2004
  18. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23:8389–8395
  19. Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, et al. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer. 2003;97:170–178
  20. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558–3585
  21. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12:1232–1237
  22. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821–1826
  23. Spiridonidis CH, Laufman LR, Carman L, Moore T, Blair S, Jones J, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol. 2001;12:89–94
  24. Natale RB. Gemcitabine and taxane combinations in non small-cell lung cancer. Clin Lung Cancer. 2000;2(Suppl. 1):S15–S21
  25. Hainsworth JD, Erland JB, Barton JH, Thompson DS, Stagg MP, Bradof JE, et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer. 2003;5:33–38
  26. Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, et al. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer. 2007;109:732–740
  27. Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol. 1997;8:191–194
  28. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286–291

PII: S0169-5002(08)00059-7

doi: 10.1016/j.lungcan.2008.02.001

Lung Cancer
Volume 62, Issue 1 , Pages 72-77 , October 2008

Article Tools

* Image Usage & Resolution